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The Question Is, My Dear Watson, Why
Did the Dog Not Bark?
The Joslin 50-Year Medalist Study
T
he Joslin Gold Medalists comprise
351 U.S. residents who have sur-
vived with type 1 diabetes for .50
years. A high proportion of Medalists re-
main free from proliferative diabetic reti-
nopathy (PDR) (42.6%), nephropathy
(86.9%), neuropathy (39.4%), or cardio-
vascular disease (51.5%). Current and
longitudinal (the past 15 years) glycemic
control were unrelated to complications.
Advanced glycation end product (AGE)
concentrations include carboxyethyl-
lysine (CEL), an AGE derived from meth-
ylglyoxal; pentosidine, a glycoxidation
ascorbate product; and carboxymethyl-
lysine(CML),aglycoxidationandadvanced
lipoxidation product. Fructose-lysine CML
and CEL were signiﬁcantly elevated in the
Medalists as compared with nondiabetic,
age-matched control subjects (N 5 23,
mean age 67.7 years). Subjects with both
CEL .5.3 mmol/mol lysine and pento-
sidine (.1.0 pmol/mg protein) were the
most likely to have any complication (7.2
times more likely) (P 5 0.001), or suffer
from nephropathy (3.1 times more likely)
(P 5 0.007), neuropathy (2.5 times more
likely) (P 5 0.005), or cardiovascular dis-
ease (2.3 times more likely) (P 5 0.002).
These data are the ﬁrst to suggest that spe-
ciﬁc AGEs may decrease risk for diabetes
complications because high current CML
and fructose-lysine concentrations were
negatively correlated with PDR develop-
ment. Previous reports indicated that
AGEs and their precursors may be impor-
tant in the pathogenesis ofdiabetes compli-
cations; however, it is unexpected that
lower current levels of CML and fructose-
lysine are inversely related to PDR devel-
opment in light of reports indicating an
association between elevations of these
AGEs measured in other tissues and ret-
inopathy. The Medalist population is
likely enriched for protective factors
against complications. The question is,
what are the protective factors?
Metabolic memory in diabetes
The notion of good metabolic memory
has been applied to the beneﬁcial effects
of an initial period of good glycemic, lipid,
and blood pressure control resulting in
effects going beyond that of the period of
neareuglycemiaandfollowedbyarebound
hyperglycemia, referred to as the Nike
patternofglycemiccontrol,yetthebeneﬁts
observed are maintained. This is good
metabolic memory and has acquired a
number of synonyms including a legacy
effect, glycemic memory, hyperglycemic
memory,amongothers(1,2).TheDiabetes
Control and Complications Trial (DCCT)
study showed that the risk of retinopathy
remained signiﬁcantly reduced in the for-
merly intensely treated subjects in the ﬁrst
4 years after completion of the trial (3).
After 10 years, in the Epidemiology of
Diabetes Interventions and Complica-
tions (EDIC) follow-up in which the
A1C levelshad converged,the rates of ret-
inopathy and proliferative retinopathy re-
mained better than in the conventional
group albeit the risk reduction was some-
what lower at 10 years than the initial
4 years (4). Diabetic nephropathy showed
reduction of microalbuminuria, clinical
albuminuria, and fewer cases of hyperten-
sion and kidney transplantation after 8
years (5). Diabetic neuropathy also fared
well with a signiﬁcant reduction of both
somatic and autonomic neuropathy at 8
years of follow-up (6). During the
17 years of follow-up of the EDIC study,
intensive therapy reduced the risk of any
cardiovascular disease and the risk of
nonfatal myocardial infarction, stroke,
or death from cardiovascular disease
(7). A beneﬁcial effect of early intensive
glycemic control was also shown for cor-
onary calciﬁcation at 7–9y e a r s( 8 )a n d
the progression of carotid intima-media
thickness (9). This beneﬁcial effect of early
glycemic control now stands in stark
contrast to the possible bad metabolic
memory or legacy of intensive glycemic
control later in the course of type 2 di-
abetes (10).
The sustained beneﬁt from early
aggressive treatment is referred to as the
legacy effect or metabolic memory, but
it is unlikely to account for the Medalist
longevity and the paradoxical relationship
of freedom from complications and
AGEs.
Unfortunately, however, the Gold
Medalist trial was initiated before 1993
when glycemic control became impor-
tant,andnoeffectwasshownonrecentor
lifetime A1C.
Whatplaguesscientistsistheinability
to predict good versus bad and under-
standing the vast differences between
individuals and even ethnic groups at
risk for complications. The notion that a
period of glycemic control improves
vascular, mitochondrial, or other func-
tions providing long-lasting effects seems
somewhat naïve in light of observations
such as those in Pima Indians who, de-
spite glycemic control, die of renal insuf-
ﬁciency because their parents did so
thereby implicating a strong genetic pre-
disposition to complications including
ApoE gene, Toll receptor, aldose reduc-
tase, angiotensin (1), and choline trans-
porter polymorphism (11), which
increase susceptibility to the negative ef-
fects of hyperglycemia if present. The
clear advantages accorded to the Joslin
Gold Medalists may reside in such pro-
tection but have yet to be studied. In
termsofidentifyingprotection,oneneeds
to examine the risk factors—not the ab-
sence of risk. The secret may lie in their
absence, which is a much more daunting
task to uncover. The clue is in the failure
of the dog to bark, my dear Watson!!! As
beautifully illustrated in his book The
Music Lesson, Victor L. Wooten points
outtheneedtolistennotonlytothenotes
buttothesilences!However,weﬁrstneed
to address the notes, i.e., the traditional
risk factors and those that may contribute
to the reduced risk by their absence or
their overexpression.
The major mechanism thought to
contribute to bad metabolic memory
includes glucotoxicity, lipotoxicity, hex-
osamine, increased polyol pathway activ-
ity, and the accumulation of AGEs.
The accumulation of AGEs may be
one of the important factors in metabolic
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groupofcompoundsoccurringasaresult
of nonenzymatic glycation of proteins,
lipids, and nucleic acids. Their role in the
complication of diabetes has recently
been reviewed (12–15) (Fig. 1).
The formation of AGEs, driven by
hyperglycemia and oxidative stress, is an
important biochemical abnormality that
accompanies diabetes and inﬂammation
in general. AGEs act to induce the cross-
linking of long-lived proteins such as
collagen andto promotevascular stiffness
alteringstructureandfunction.AGEsalso
interact with cellular receptors to induce
cellular signaling leading to enhanced
oxidative stress thereby irreversibly mod-
ifying mitochondrial function. The accu-
mulationofAGEs inskinwith anincrease
inCMLandglycatedcollagenhasrecently
been obtained from skin biopsies in the
DCCT/EDIC study (16) with the predic-
tionofprogressionofretinopathyand ne-
phropathy even controlling for A1C. In
the Gold Medalist study, current and lon-
gitudinal (the past 15 years) glycemic
control were unrelated to complications.
Subjects with high plasma CEL and pen-
tosidine were 7.2-fold more likely to have
any complication. The AGE results
conﬁrmarobustassociation with compli-
cations and suggest that AGE formation
may be independent of glycemia (Fig. 1).
The association of complications with
CEL implicates increased methyglyoxal
production, which itself is associated
with various cellular and matrix dysfunc-
tions (17), while increased pentosidine
likely reﬂects increased ascorbic acid deg-
radation because of oxidant production.
Of the Medalists without PDR, 96% with
no retinopathy progression over the ﬁrst
17 years of follow-up experienced wors-
ening retinopathy thereafter. The great
paradox in the Medalist study is the ob-
servation that the unique combination
of AGEs were predictive of the develop-
ment of microvascular complications of
diabetes but at follow-up the relation be-
tween AGEs and complications were in-
verse suggesting that 1) other pathways
may be involved, 2) there were compen-
satory mechanisms operating with time,
or 3) the body had a self-contained de-
fense mechanism for AGE interaction
with its receptor(s) with the elaboration
of subsequent events. Thus, an adaptive
mechanism, which can alter the process-
ing of CML and fructose-lysine, may pro-
vide protection against development of
PDR and possibly other complications of
diabetes.Ifso,thenwhatarethesedefense
mechanisms?
AGEshavealsobeenimplicatedinthe
development of neuropathy and most
recently in Charcot neuroarthropathy
(18). The highest AGE levels are found
in tissues with the slowest turnover such
as skin, tendon, bone, amyloid plagues,
and cartilage (19). The AGE/receptor for
AGE (RAGE) axis is a likely mechanism
linking microangiopathy and neuropathy
Figure 1—The relationship between binding of ligands to the pattern recognition AGE receptor, RAGE and inﬂammation, gene expression,
oxidative and nitrosative stress, and damage to the macro- and microvasculature. Elevated levels of glucose bind to proteins and form AGEs (I),
whichbindtoRAGEs.RAGEsignalingactivatesNADPHoxidase(II)andproductionofreactiveoxygenspecies(ROS)(III).IncreasedROSincreases
advance oxidation protein products (AOPPs), more AGEs, and AGE-modiﬁcation of oxidized LDLs (oxLDLs). Furthermore, increased ROS may
deplete glutathione, thereby suppressing glyoxalase I activity, a mechanism favoring further AGE accumulation (IV). AGEs, AOPPs, macrophage
glycoprotein (MAC-1), and AGE-oxLDL ligands of RAGE sustain stimulation of RAGE, and these processes, together with increased ROS, activate
key transcription factors such as nuclear factor-kB (NF-kB) and Egr-1 (V), which increase gene transcription factors and activate inﬂammatory
mechanisms(VI).ConsequencesincludeincreasedmigrationandactivationofRAGE-expressingneutrophils,monocytes/macrophages,T-cells,and
dendritic cells (VII). This results in the release of the proinﬂammatory RAGE ligands S100/calgranulins and high-mobility group protein box-1
(HMGB1). In this inﬂammatory environment, further AGEs may be formed as well. Via interaction with RAGE, these ligands magnify activation of
NF-kB,Agr-1,andotherfactors(VIII),therebyamplifyingcellularstressandtissuedamageleadingtoneurovascularandbonedysfunction.Soluble
RAGE(sRAGE)formedfromcleavageofRAGEbydisintegrinssuchasADAM10,ametalloproteinase,andb-andg-secretases.sRAGEoraspliced
variant (esRAGE) compete for binding of ligands to RAGE, and a deﬁciency could theoretically initiate the sequence of events activating an in-
ﬂammatory cascade with an increase in the expression of proinﬂammatory cytokines (E-selectin, endothelin-1 tissue factor, vascular endothelial
growth factor, and other proinﬂammatory cytokines [interleukin-6 and tumor necrosis factor-a]) and damage to neurons, kidney, eye, the vas-
culature, and even bone. Increasing sRAGE or its administration could competitively reduce activation of the AGE/RAGE pathway and it con-
sequences. Modiﬁed with permission from Yan et al. (14). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Viniksupportedbytheﬁndingofcolocalization
of CML, RAGE, nuclear factor-kB, and
interleukin-6 to epineural vessels, peri-
neurium, and endoneurial blood vessels.
AGEs have been demonstrated in murine
models to worsen nerve conduction ve-
locity and blood ﬂow to nerves (20). Ad-
ministration of AGEs duplicate the effects
of hyperglycemia and can be neutralized
by anti-AGE antibodies (21,22). How-
ever, even in RAGE null mice, the activa-
tion of the inﬂammatory process is
incompletely inhibited suggesting that
AGE/RAGE may be an incomplete part
of the mechanism for the development
ofneuropathy.Inthekidneyandpossibly
in the eye, there are signiﬁcant increases
in the accumulation of AGEs including
basementmembranethickening,mesangial
expansion, glomerulosclerosis and tubu-
lointerstitial ﬁbrosis, and increased colla-
gen1Vandtransforminggrowthfactor-b.
The AGE blocker aminoguanidine, a
cross-link breaker known as alagebrium,
and treatment with soluble RAGE
(sRAGE) have been shown to reduce the
renal damage of diabetes (12). AGEs may
negatively inﬂuence bone by interfering
with osteoblast differentiation and the
production of important matrix proteins
such as collagen and osteocalcin. AGEs
have also been shown to stimulate apo-
ptosis of human mesenchymal stem cells
(23) and osteoblast apoptosis through a
nuclear factor-kB–independent mecha-
nism that further limits bone formation
(24). A proposed mechanism through
which diabetes induces apoptosis by
stimulating AGEs is via CML-collagen,
mediated through RAGE, the pattern rec-
ognitionreceptorforAGE.However,ade-
coy mechanism is found in which AGEs
and other ligands (14) bind to RAGE a
circulatingformofRAGEandtherebypre-
clude access of the RAGE ligand to sRAGE
mitigating the activation of the pathways
of oxidative and nitrosative stress. Al-
though not reported in the Gold Medalist
study, measurements of circulating sRAGE
may well have contributed further to the
understanding of the protection afforded
these individuals. While it appears that
RAGE knockouts experience protection
from complications of diabetes, gene
polymorphisms of the multitude of regu-
latory sites for control of AGE/RAGE in-
teractions have been suggestive but none
can be held accountable for the protec-
tion or susceptibility to complications of
diabetes (13).
Witzke et al. (18) reported on a
50% reduction in circulating sRAGE in
diabetesandan85%reductioninpatients
with Charcot neuroarthropathy. Geroldi
et al.(25) studied centenarians and found
sRAGE levels that were inordinately high,
suggesting that sRAGE is a marker of
health and/or an innate protective mech-
anism for complications of diabetes. Can
sRAGE levels be changed? It has been
shown that certain drugs can raise sRAGE
levels (e.g., a-lipoic acid, benfotiamine,
vitamin C, ACE inhibitors, statins, and
glitazones) (14), suggesting that these
medications may have a role in the pre-
vention of complications of diabetes. Al-
ternatively the availability of sRAGE
suggests a potential means of treating or
preventing complications of diabetes.
Pyridoxamine is a vitamin B6 derivative
thatpreventsdegradationofproteinAma-
dori products to their AGE equivalents
and has been shown to decrease micro-
albuminuria and other elements of renal
dysfunction. Putative cross-link breakers
such as N-phenacylthiaxolium bromide
and a stable derivative alagebrium, ALT
711, have shown salutary effects on
RAGE accumulation in several tissues
with improvement in albuminuria and
cardiac collagen 111 expression and
have improved ejection fractions and ar-
terial stiffness in clinical trials (12).
Benfotiamine, a lipid-soluble thiamine
derivative (B1), prevents activation of
three main pathways of hyperglycemia
damage—hexosamine, intracellular AGE
formation, and the diacylglycerol kinase
pathway—by inhibiting the action of
transketolase in renal glomeruli–reduced
microalbuminuria (26,27). Benfotiamine
improves nerve function in the peroneal
nerve(28)andalleviatesneuropathicpain
(29) in diabetic humans. Benfotiamine
reduces the microvascular and macrovas-
cular endothelial dysfunction and oxida-
tive stress after a high AGE meal (30).
Indeed angiotensin 11 inhibitors lower
AGE levels and increase the expression
of sRAGE as a potential decoy. Drugs
such as thiazolidinediones, metformin,
and angiotensin receptor blockers have
been shown to decrease AGE formation
andpromote AGEclearance and degrada-
tionpossiblybyinducingtheformationof
sRAGE. Even dietary restriction of AGEs
may have signiﬁcant effects upon AGE
accumulation in clinical diabetes and an-
imal models of diabetes complications
(12). This leads us to wonder if in the
early years of the DCCT, before it became
fashionable, the Joslin Gold Medalists re-
duced their intake of AGEs and enhanced
their capacity to clear AGEs by one of the
mechanisms outlined and, with time, the
inverse correlation reﬂe c t e do n l ya ni n -
complete compensation of the AGE/
RAGE mechanism and not that they
had any less damage potential. We ea-
gerly await studies on the haloed who
remain free of complications of diabetes
because this will offer new therapeutic
potential in an area hungry for novel
forms of intervention.
Other theories on the mechanism for
metabolic memory include the possibility
thatthereisalongprodromethatprecedes
theadventofhyperglycemiainwhichthere
are increases in inﬂammatory cytokines
such as interleukin-6 and tumor necrosis
factor-a,inoxidativeandnitrosativestress,
and in the selectins such as E-selectin and
P-selectin(1,31).Goodmetabolicmemory
may derive from suppression of these
proinﬂammatory cytokines despite failure
of glycemic control by e.g., insulin (1) and
episodic spikes inglucose(32). The roleof
anti-inﬂammatory agents, particularly
those involving the cyclooxygenase path-
ways with reduction in neuropathy, reti-
nopathy, and nephropathy in mice with
5- and/or 12-lipoxygenase knockouts
(33–35), further suggest that novel
mechanismsmaycontributetometabolic
m e m o r ya n dc o n f e ra d v a n t a g e si ni n d i -
viduals protected from the ravages of
diabetes.
There is no doubt that the absence of
evidenceisnotevidenceofabsencebut,in
thisinstance,thereshouldbeagreatreturn
fromthestudyofwhythedogdidnotbark
among the Joslin Gold Medalist survivors,
and what the compensatory mechanisms
are for defense against the storm of AGE/
RAGE interaction.
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